Common Stock, par value $.0001 per share
- Symbol
- XAIR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 7.01, 9.01 · 8-K
Beyond Air, Inc.
XAIRNASDAQEQUITYCurrent
Results of Operations and Financial Condition · Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The information under Item 2.02 above is incorporated herein by reference. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.…
Press release in this filing
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update →Company context
Current securities
Historical securities (1)
Registered securities in this filing
Beyond Air, Inc. · 8-K · Filed 2026-02-13
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure
The
information under Item 2.02 above is incorporated herein by reference.
By
filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality
of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information in this Item 7.01
disclosure, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the
Exchange Act, or otherwise subject to the liabilities under that Section. In addition, the information in this Item 7.01 disclosure,
including Exhibits 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act, or the Exchange
Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1 Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to provide runway into calendar 2027 Signed binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air’s subsidiary NeuroNOS; Beyond Air to receive up to $32.5 million from the combination of upfront cash, development and commercial milestones and 19.99% equity ownership in XTL Biopharmaceuticals Phase 1a data from UNO program in solid tumors to be presented at AACR Annual Meeting in April 2026 Conference call at 8:00 a.m. ET today, February 13th Garden City, NY, February 13, 2026 - Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced its financial results for the fiscal third quarter end…
Open exhibit ↗